“PIM kinase fragments”, image courtesy of Jens Petersen, AstraZeneca


An EFMC sponsored event


Fragments 2017

6th RSC-BMCS Fragment-based Drug Discovery meeting

Sunday to Tuesday, 5th to 7th March 2017

at Parkhotel Schönbrunn, Vienna, Austria

 

Click image to the top left for flier download.

 

Registration is closed

 

Downloads and Links

Second announcement

First announcement

 

Poster listing with numbers

 

Venue travel directions

RSC website

Synopsis

The aim of the 6th RSC-BMCS Fragment-based Drug Discovery meeting was to continue the focus on case studies in Fragment-based Drug Discovery that have delivered compounds to late stage medicinal chemistry, preclinical or clinical programmes. The Fragment series was started in 2007 and continues with the theme, having over three-quarters of the presentations focused on case studies. The conference included successful examples from all types of fragment-based approaches, including high concentration, NMR, SPR and X-ray screening.

Who should attend

This conference was suitable for scientists including all chemists as well as other important disciplines including biophysics, structural biology, etc. This international meeting attracted delegates from the UK, several mainland European countries, as well as from the USA, Japan, Taiwan, Singapore, India, Australia and Mexico.

Pre-conference Workshop
The pre-conference workshop offered those new to the area of FALG/FBLG an introduction into the fundamental principles governing fragment-based drug discovery approaches. A series of five short presentations with opportunities for discussions were scheduled. The pre-conference workshop was offered free-of-charge to conference attendees (opt-in required).

 

Call for Posters
The call for posters closed on 20th January.   Selected student speakers were invited to present at the flash presentation session prior to the poster session. 

 

Programme   Where presentation titles are highlighted in orange, you may download the .pdf of the presentation

Sunday, 5th March - optional pre-conference workshop

14:30 Registration opens

15:00

 

Introduction to FBLG/FBDD – background
Thorsten Nowak, C4X Discovery, UK

15:30 Fragment screening: some theory and what to expect in terms of quality of hits
Mike Hann, GlaxoSmithKline, UK

16:00

 Fragment screening methods
Samantha Hughes, AstraZeneca, UK
16:30 Refreshments
17:00 Fragment optimisation
Mark Whittaker, Evotec, UK
17:30 

Fragment optimisation and PPIs

Darryl McConnell, Boehringer Ingelheim, Austria

18:00 

Close

18:45 Buffet dinner at the hotel

Monday, 6th March

09:15  Registration and refreshments

10:00

 

Opening remarks

Darryl McConnell, Boehringer Ingelheim, Austria

10:10

 

Session chair:  Mike Hann, GlaxoSmithKline, UK

10:10

 

Targeting protein protein interactions in oncology using a fragment-based drug discovery approach

Justin Bower, Beatson Institute, UK

10:55 

Novel inhibitors of iNOS discovered through FBLG
Fredrik Edfeldt, AstraZeneca, Sweden

 

 

Flash poster presentations

11:40 Fragment-based design of carbonic anhydrase III inhibitors as potential anti-obesity agents
Areej Abuhammad, University of Jordan, Jordan
11:42 Towards antibiotic resistance breakers: fragment-based design of OXA- 48 inhibitors
Annette Bayer, The Arctic University of Norway, Norway
11:44 Purinome targeted, fragment based lead discovery: identification of noel HSP90 inhibitors
Francesco Casuscelli, Nerviano Medical Sciences, Italy
11:46 Targeting protein-protein interfaces in influenza and ebola viral targets using fragment screening
Douglas Davies, Beryllium Discovery, USA
11:48 Design and synthesis of 3-dimensional fragments to explore pharmaceutical space
Tom Downes, University of York, UK
11:50 Synthesis of DSB inhibitors as novel antibacterial drugs
Luke Duncan, La Trobe University, Australia
11:52 To design and develop chemistry to make novel high quality fragments
Nicola Luise, University of Dundee, UK
11:54 Screening and optimisation of molecular fragments that bind to the protein component of bacterial Ribonuclease P as a platform to characterise its pharmacobiological properties
Alejandro Madrigal-Carrillo, Universidad Nacional Autonoma de Mexico, Mexico
11:56 Fragment screening against the lysine methyltransferase G9a using microscale thermophoresis
Nick Martin, Domainex, UK
11:58 Biophysical, biochemical and fragment-based approaches towards blocking the Aurora-A/TPX2 interaction
Patrick McIntyre, University of Leicester, UK
12:00 

Identifying inhibitors of the Tankyrase : substrate protein-protein interaction
Katie Pollock, The Institute of Cancer Research, UK

Poster prize winner!

12:02 

The patent landscape of fragment-based drug discovery
Angelo Kenneth S Romasanta, VU Amsterdam, The Netherlands

12:04 Fragment-based identification of inhibitors against influenza virus neuraminidase
Yun Shi, Griffith University, Australia
12:06 Exploring fragments to improve BP-1-102 ligand efficiency for stronger inhibitory effects on STAT3
Po-Chang Shih, University College London, UK
12:08 Strength of Weak Affinity Chromatography (WAC): elucidating target interactions of synthetic fragment mixtures
Prachi Singh, Nanyang Technological University, Singapore
12:10 DyNAbind: applying DNA-encoded library technology to fragment-based drug discovery
Michael Thompson, TU Dresden - DyNAbind. Germany
12:12 Fragment based discovery of molecules targeting Aspergillus fumigatus Rho1 GTPase
Wenfan Wei, University of Dundee, UK

12:14

 

Lunch and posters

 

13:00 Session chair:  Samantha Hughes, AstraZeneca, UK
13:00 

Finding better fragments faster with MST
Dennis Breitsprecher, NanoTemper, Germany

13:45

 

Addressing novel targets by crystallography with fragments and self-optimized inhibitors

Gerhard Klebe, University of Marburg, Germany

14:30 Scanning the protein surface to uncover new small molecule binding sites using fragments  due
Gregg Siegal, ZoBio, The Netherlands

15:15

 

Refreshments

15:45

 

New scaffolds targeting DNA gyrase – fragment optimization and structure based drug design

Dominic Ryan, formerly Cubist, USA

16:30 

AbbVie’s re-vamped fragment-based drug discovery platform

Phil Cox, AbbVie, USA

17:15 

Poster session and drinks reception

18:15 Close
19:15 

Conference dinner in the hotel Ballroom

Tuesday, 7th March

09:00

 

Session chair:  Thorsten Nowak, C4X Discovery, UK

09:00

 

Fragment optimisation without co-crystal X-ray structures: from hits to nanomolar inhibitors of human PAICS

Simon Osborne, MRC Technology, UK

09:45 

Leveraging iterative 3D-structure information while managing physicochemical properties: design of eFT508, an oral, potent and highly selective inhibitor of mitogen-activated protein kinase interacting kinase (MNK) 1 and 2

Siegfried Reich, eFFECTOR, USA

10:30

 

Refreshments

11:00 

Computational approaches to fragment-based drug discovery

Paul Mortenson, Astex Pharmaceuticals, UK

11:45

 

Advances in fragment-based drug discovery applied to membrane protein drug targets

Michael Hennig, leadXpro AG, Switzerland

12:30

 

Lunch and posters

13:30 

Session chair:  Mark Whittaker, Evotec, UK

13:30 

Training early stage researchers in FBDD, two examples of European training networks

Iwan de Esch, VU Amsterdam, and Christian Ottmann, University of Eindhoven, The Netherlands

14:15

 

Innovating drug discovery by locking GPCRs in functional conformations

Christel Menet, Confo Therapeutics, Belgium

15:00

 

Refreshments

15:30

 

BCL6 Inhibitors – From micro-molar binders to nano-molar degraders

Steffen Steurer, Boehringer Ingelheim, Austria

16:15 

Cancer drug discovery using fragment-based methods and structure-based design

Stephen W Fesik, Vanderbilt University, USA

17:30 

Closing remarks

Gordon Saxty, Fidelta, Croatia

Bursaries and Sponsorship
Bursaries were made available based on sponsorship of the event. If you wished to sponsor students to expand their knowledge in this area, you were asked to contact the secretariat for further information.

 

We are grateful to our sponsors for their support of this event.

Exhibition Opportunities
Those companies who wished to have a trade stand were encouraged to apply early.


£825   Exhibition trade stand only (excludes attendees) – fixed rate
£146   Stand staff with no access to technical programme, excluded conference dinner
 £69    Conference dinner for stand staff (Monday evening) – fixed rate

£275   Delegate pack insert

 

Each exhibition stand comprised:

- Space measuring 3 m wide x 2 m deep maximum
- Table measuring 140 x 70 x 75 cm with cloth and chair(s)
- Electrical access and wi-fi access

- Logo in delegate handbook

- Single A4 promotional page (portrait) in delegate handbook (printed black and white)

Registration and Fees
Registration is closed, and registration fees are below.

Registration fees included the Sunday afternoon workshop and buffet dinner, and Monday evening conference dinner (opt in required).
 

Early rates for payments received by 2nd January
£363  RSC member
£460  Non-member
£188  RSC student* member
£236  Student* non-member

Standard rates for payments received between 3rd January and 3rd February
£436  RSC member
£544  Non-member
£224  RSC student* member
£278  Student* non-member

Late booking fee for payments received after 3rd February
£55  Late payment fee will be added to the above standard rates

* Student is undergraduate or post-graduate, not post-doc, and does not apply to students in paid employment.
Member is paid-up member of the RSC.

Cancellation Policy
In the event of cancellation before 12th February 2017, 80% of the fee paid will be refunded. Cancellations must be received in writing.  Refunds will not be possible after that date although substitutions are possible at any time.

Accommodation fees were only refunded (in line with the policy above) if the room could be resold.

In the unlikely event of cancellation of the meeting, fees paid will be refunded in full. Registration acknowledgements will be sent within two weeks.
Accommodation
Accommodation at the Parkhotel Schönbrunn, the conference hotel, could have been booked at the time of registration.    B&B accommodation (Sunday and Monday) in a deluxe en-suite bedroom (single occupancy) was priced at £99.

Check-in was from 3 pm, and check-out was by 12 midday.  Luggage storage was available, adjacent to reception.

Conference Dinner
The conference dinner was held at the conference hotel, the Parkhotel Schönbrunn, in the glorious ballroom.  This hotel was the former guest house of Emperor Franz Joseph I.   This dinner was included in the registration fee (opt-in required).

Venue and Travel
Address: Austria Trend Parkhotel Schönbrunn, Hietzinger Hauptstrasse 10-14, 1130 Vienna, Austria
 

Hotel Overview:  Originally built in 1787, this imperial hotel has suffered two fires and is in the restored former guest house of Emperor Franz Joseph I. It has been a rest stop, an inn, a lavish ballroom, an art showroom, a military hospital, an officers’ mess, and now a modern hotel with imperial nostalgia.

 

Travel Overview:  Austria has an excellent public transport system, and distances from the hotel are: railway station 4.5 miles, city centre 5.5 miles, and airport 15 miles. 

 

Location Map:  A location map may be found here.

 

Public Transport
T
he nearest railway station to the hotel is Westbahnhof.
The nearest metro line to the hotel is metro U4, and the stop is called Hietzing.

 

- From Vienna airport, take the Vienna Airport Lines bus, which runs to destinations within Vienna, such as Schwedenplatz stop in order to pick up the U4 metro which runs to the hotel, Hietzing stop.
- From Vienna Westbahnhof railway station, take tram 58 to Hietzing stop.

 

Journey Times:  Approximate journey times are:
- 40-45 minutes from airport to hotel by taxi (depends on traffic)
- 60 minutes from airport to hotel by bus
- 20 minutes from Westbahnhof railway station to hotel by taxi
- 15 minutes from Westbahnhof railway station to hotel by bus

Organising Committee

Mike Hann

 

GlaxoSmithKline

Samantha Hughes AstraZeneca
Darryl McConnell Boehringer Ingelheim

Thorsten Nowak

 

C4X Discovery Ltd

Gordon Saxty (chairman)

 

Fidelta

Mark Whittaker

 

Evotec

 

Registration is closed